CASI Pharmaceuticals Inc (NASDAQ:CASI) Stock is All Set To Gap-Up: But Why?
CASI Pharmaceuticals Inc (NASDAQ:CASI) up 35% in premarket after reporting Q2 2021 financial results in which the company realized $7.1 million in EVOMELA revenues. Analysts had predicted that the company would post a 130.3% YoY revenue increase to $6.15 million with a loss per share of $0.09 during the quarter. CEO Wei-Wu He stated that they are revising full-year 2021 revenue guidance based on the current trend, which is expected…